News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Inyx, Inc.'s Ashton Pharmaceuticals Selected To Produce Generic Drugs For European Markets


7/17/2006 11:50:09 AM

NEW YORK, July 17 /PRNewswire-FirstCall/ -- Inyx, Inc. , a specialty pharmaceutical company focused on niche drug delivery technologies and products, announced today that its wholly owned U.K. subsidiary, Ashton Pharmaceuticals Ltd., has been selected by a leading Indian specialty pharmaceutical company to manufacture a range of generic drugs for the United Kingdom and other European countries.

Ashton will initially provide process transfer services to enable production of the tablet products at commercial batch sizes. Ashton will then manufacture and package the entire range of generic products.

Jack Kachkar, M.D., Chairman of Inyx, Inc., said, "We are very pleased that Inyx has been selected for the commercial production of this client's generic drugs. This reflects Ashton's in-depth capabilities to enable clients to bring products rapidly to market."

Inyx, last August, acquired Ashton, which expanded its expertise into solid dose as well as injectable pharmaceuticals and enhanced its capabilities in dry powder inhalers. The company has another U.K. subsidiary, Inyx Pharma Ltd., which specializes in metered dose inhalers, metered dose nasal and oral sprays, hydrocarbon foam formulations and sterile saline solutions.

About Inyx

Inyx, Inc. is a specialty pharmaceutical company with niche drug delivery technologies and products for the treatment of respiratory, allergy, dermatological, topical and cardiovascular conditions. Inyx focuses its expertise on both prescription and over-the-counter pharmaceutical products, and provides specialty pharmaceutical development and production consulting services. In addition, Inyx is developing its own proprietary products. The company's operations are conducted through several wholly owned subsidiaries: Inyx USA Ltd., based in Manati, Puerto Rico; Inyx Pharma Ltd. and Inyx Europe Limited, which owns and operates Ashton Pharmaceuticals Ltd., all near Manchester, England; Inyx Canada, Inc. in Toronto; and Exaeris, Inc., based in Exton, Pennsylvania, which conducts Inyx's marketing and distribution activities. Inyx, Inc.'s corporate offices are in New York City. For more information, please visit: http://www.inyxgroup.com.

Safe Harbor

Statements about the Inyx's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. Inyx intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, Inyx's actual results could differ materially from expected results.

For more information, please contact: Jay M. Green, Executive Vice President of Inyx, Inc. jgreen@inyxgroup.com Bill Kelly, Vice President Investor Relations of Inyx, Inc. bill.kelly@inyxgroup.com

Inyx, Inc.

CONTACT: Jay M. Green, jgreen@inyxgroup.com, or Bill Kelly,bill.kelly@inyxgroup.com, both of Inyx, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES